| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net revenue | ||||||||||||||||
265,590 | 260,981 | 249,935 | 236,439 | 215,043 | 193,449 | 182,992 | 183,681 | 194,200 | 198,508 | 0 | 0 | 0 | - | - | - | - |
Cost of goods sold | ||||||||||||||||
77,761 | 75,948 | 73,067 | 73,413 | 71,267 | 68,808 | 67,720 | 64,330 | 62,436 | 61,220 | 0 | 0 | 0 | - | - | - | - |
Gross profit | ||||||||||||||||
187,829 | 185,033 | 176,868 | 163,026 | 143,776 | 124,641 | 115,272 | 119,351 | 131,764 | 137,288 | 0 | 0 | 0 | - | - | - | - |
Operating expenses: | ||||||||||||||||
Selling, general and administrative | ||||||||||||||||
203,413 | 199,693 | 194,803 | 183,911 | 172,689 | 161,961 | 150,870 | 147,949 | 143,930 | 133,717 | 0 | 0 | 0 | - | - | - | - |
Research and development | ||||||||||||||||
16,838 | 14,799 | 14,250 | 13,105 | 11,289 | 10,742 | 10,386 | 9,932 | 10,338 | 9,065 | 0 | 0 | 0 | - | - | - | - |
Write-off of deferred offering costs | ||||||||||||||||
- | - | - | 0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - |
Total operating expenses | ||||||||||||||||
220,251 | 214,492 | 209,053 | 197,016 | 187,472 | 176,197 | 0 | 0 | 0 | - | - | - | - | 208 | 0 | 0 | 0 |
Loss from operations | ||||||||||||||||
-32,422 | -29,459 | -32,185 | -33,990 | -43,696 | -51,556 | -49,478 | -42,024 | -22,504 | -5,494 | -4,390 | -1,788 | 0 | 0 | 0 | - | - |
Other expense, net: | ||||||||||||||||
Interest expense, net | ||||||||||||||||
9,728 | 8,996 | 9,055 | 9,568 | 10,162 | 10,813 | 10,433 | 9,726 | 8,976 | 8,139 | 0 | 0 | 0 | - | - | - | - |
Interest income | ||||||||||||||||
- | - | - | - | - | 64 | - | - | 110 | 129 | 0 | 0 | 0 | - | - | - | - |
Change in fair value of warrants | ||||||||||||||||
- | - | - | 0 | - | 469 | 352 | 836 | 1,166 | 1,037 | 0 | 0 | 0 | - | - | - | - |
Loss on the extinguishment of debt | ||||||||||||||||
- | -1,862 | -3,957 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - |
Gain on settlement of deferred acquisition consideration | ||||||||||||||||
0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Other income, net | ||||||||||||||||
-98 | 13 | 161 | 171 | 289 | 162 | 61 | 51 | -66 | -9 | 0 | 0 | 0 | - | - | - | - |
Total other expense, net | ||||||||||||||||
-8,531 | -10,845 | -13,016 | -13,569 | -14,220 | -13,191 | -10,677 | -10,436 | -10,098 | -9,056 | 0 | 0 | 0 | - | - | - | - |
Net loss before income taxes | ||||||||||||||||
-40,953 | -40,304 | -45,201 | -47,559 | -57,916 | -64,747 | -60,155 | -52,460 | -32,602 | -14,550 | 0 | 0 | 0 | - | - | - | - |
Income tax expense | ||||||||||||||||
148 | 150 | 110 | 89 | 93 | 84 | -151 | -131 | -314 | -7,025 | 0 | 0 | 0 | - | - | - | - |
Net loss | ||||||||||||||||
- | - | - | -47,648 | - | -64,831 | - | -52,329 | -32,561 | -8,388 | 0 | 0 | 0 | - | - | - | - |
Net income attributable to non-controlling interest in affiliates | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | - |
Net loss | ||||||||||||||||
0 | - | 0 | - | 0 | -64,831 | 0 | - | - | -7,525 | -3,275 | 2,113 | 2,081 | -208 | 0 | 0 | 0 |
Non-cash deemed dividend to warrant holders | ||||||||||||||||
- | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net loss attributed to Organogenesis Holdings Inc. common shareholders | ||||||||||||||||
- | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net loss per share—basic and diluted | ||||||||||||||||
-0.16 | -0.04 | -0.12 | -0.11 | -0.17 | -0.12 | -0.19 | -0.30 | -0.35 | - | - | - | - | -0.02 | 0.00 | 0.00 | 0.00 |
Weighted-average common shares outstanding—basic and diluted | ||||||||||||||||
104,486 | 97,833 | 92,276 | 90,647 | 90,604 | 76,952 | 69,496 | 66,361 | 64,320 | - | - | - | - | 9,184 | 7,500 | 7,500 | 7,500 |